Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: A network meta-analysis

Diabetic Medicine

Volumn 32, Issue 12, 2015, Pages 1530-1540

  Mearns, E S ^a,b   Saulsberry, W J ^a,b   White, C M ^a,b   Kohn, C G ^c   Lemieux, S ^a   Sihabout, A ^a   Salamucha, I ^a   Coleman, C I ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

^c UNIVERSITY OF SAINT JOSEPH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; EXENDIN 4; HEMOGLOBIN A1C; INSULIN GLARGINE; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; VILDAGLIPTIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SULFONYLUREA DERIVATIVE;

ALBUMINURIA; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; ELEVATED BLOOD PRESSURE; GENITAL TRACT INFECTION; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAXIMUM TOLERATED DOSE; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION; WEIGHT GAIN; ADVERSE EFFECTS; BLOOD; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; DRUG RESISTANCE; EVIDENCE BASED MEDICINE; HYPERGLYCEMIA; PERSONALIZED MEDICINE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

DIABETES MELLITUS, TYPE 2; DRUG MONITORING; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; PRECISION MEDICINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONYLUREA COMPOUNDS;

EID: 84983094627     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12837     Document Type: Article

References (45)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140-149.
2. Campbell RK. Fate of the beta-cell in the pathophysiology of type 2 diabetes. J Am Pharm Assoc 2009; 49(Suppl. 1): S10-S15.
3. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
4. Haring HU, Merker L, Seewaldt-becker E, Weimer M, Meinicke T, Woerle HJ et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013; 26: 3396-4404.
5. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
6. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP et al. Glycemic durabil- ity of rosiglitazone, metformin, or gly- buride monotherapy. N Engl J Med 2006; 355: 2427-2443.
7. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010; 303: 1410-1418.
8. Wilding JP, Charpentier G, Hollander P, González-Gálvez G, Mathieu C, Vercruysse F et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013; 67: 1267-1282.
9. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at www.cochrane-handbook.org. Last accessed 27 June 2014.
10. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
11. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011; 14: 429-437.
12. Package 'netmeta'. June 24, 2014. Available at http://cran.r-project.org/web/packages/netmeta/netmeta.pdf. Last accessed 27 June 2014.
13. Rücker G. Network meta-analysis, electrical networks and graph theory. Research Synthesis Methods 2012; 3: 312-324.
14. Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency in networks of interventions. Int J Epidemiol 2013; 42: 332-345.
15. Evaluate inconsistency in a network of trials. Available at http://www.mtm.uoi.gr/index.php/ how-to-do-an-mtm/10-how-to-do-an-mtm/18-inconsistency. Last accessed 9 March 2015.
16. Moses RG, Kalra S, Brook D, Sockler J, Monyak J, Visvanathan J et al. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Diabetes Obes Metab 2014; 16: 443-450.
17. Lukashevich V, Prato SD, Araga M, Kothny W. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes Metab 2014; 16: 403-409.
18. AstraZeneca. Evaluation of safety and efficacy of dapagliflozin in subjects with type 2 diabetes who have inadequate glycaemic control on background combination of metformin and sulfonylurea. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available at http://clinicaltrials.gov/ct2/show/results/NCT01392677?term=01392677&rank=1 NLM Identifier: NCT01392677. Last accessed 17 July 2014.
19. Merck Sharp & Dohme Corp. A study to evaluate the safety and efficacy of sitagliptin 100 mg in participants with type 2 diabetes mellitus who have inadequate glycemic control (MK-0431-229). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available at http://clinicaltrials.gov/ct2/show/NCT01076075?term=01076075&rank=1 NLM Identifier: NCT01076075. Last accessed 17 July 2014.
20. Liu SC, Chien KL, Wang CH, Chen WC, Leung CH. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea. Endocr Pract 2013; 19: 980-988.
21. Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013; 36: 3396-3404.
22. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013; 36: 2508-2515.
23. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011; 28: 1352-1361.
24. Kadoglou NP, Iliadis F, Sailer N, Athanasiadou Z, Vitta I, Kapelouzou A et al. Exercise training ameliorates the effects of rosiglitazone on traditional and novel cardiovascular risk factors in patients with type 2 diabetes mellitus. Metabolism 2010; 59: 599-607.
25. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046-2055.
26. Charpentier G. Halimi S; F-PIO-100 Study Investigators. Earlier triple therapy with pioglitazone in patients with type 2 diabetes. Diabetes Obes Metab 2009; 11: 844-854.
27. Kadoglou NP, Iliadis F, Angelopoulou N, Perrea D, Liapis CD, Alevizos M. Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus. Diabet Med 2008; 25: 333-340.
28. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9: 733-745.
29. Triplitt C, Glass L, Miyazaki Y, Wajcberg E, Gastaldelli A, De Filippis E et al. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea. Diabetes Care 2006; 29: 2371-2377.
30. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006; 29: 554-559.
31. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559-569.
32. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091.
33. Dailey GE 3rd, Noor MA, Park JS, Bruce S, Fiedorek FT. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med 2004; 116: 223-229.
34. Lam KS, Tiu SC, Tsang MW, Ip TP, Tam SC. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study. Diabetes Care 1998; 21: 1154-1158.
35. American Diabetes Association. Executive summary: Standards of medical care in diabetes-2014. Diabetes Care 2014; 37(Suppl. 1): S5-S13.
36. Sullivan PW, Morrato EH, Ghushchyan V, Wyatt HR, Hill JO. Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000-2002. Diabetes Care 2005; 28: 1599-1603.
37. Fonseca V, Mcduffie R, Calles J, Cohen RM, Feeney P, Feinglos M et al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care 2013; 36: 2162-2168.
38. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011; 13: 669-672.
39. Parving HH, Persson F, Rossing P. Microalbuminuria: a parameter that has changed diabetes care. Diabetes Res Clin Pract 2015; 107: 1-8.
40. Hall JE, Brands MW, Henegar JR. Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney. J Am Soc Nephrol 1999; 10(Suppl. 12): S258-S265.
41. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-713.
42. Scholes D, Hooton TM, Roberts PL, Gupta K, Stapleton AE, Stamm WE. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med 2005; 142: 20-27.
43. Anderson ER Jr, Koplan J, Henney JE, Billy TJ. Diagnosis and management of foodborne illness: a primer for physicians. MMWR Recomm Rep 2001; 50: 1-69.
44. Gross JL, Kramer CK, Leitão CB, Hawkins N, Viana LV, Schaan BD et al. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med 2011; 154: 672-679.
45. McIntosh B, Cameron C, Singh SR, Yu C, Ahuja T, Welton NJ et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med 2011; 5: e35-e48.